title: In vivo effects of adjunctive tetracycline treatment on refractory corneal ulcers in dogs.
abstract: OBJECTIVE
  To evaluate effect of adjunctive treatment with tetracycline analogues on time to complete corneal reepithelialization in dogs with nonhealing (ie, refractory) corneal ulcers.
  
  
  METHODS
  Randomized controlled clinical trial.
  
  
  METHODS
  89 dogs with refractory corneal ulcers.
  
  
  METHODS
  Corneal ulcers were treated via debridement and grid keratotomy. Dogs were assigned to receive 1 of 3 treatment regimens for up to 6 weeks: doxycycline (5 mg/kg [2.27 mg/lb], PO, q 12 h) with topically applied ophthalmic ointment containing neomycin, polymyxin B, and bacitracin (ie, triple antibiotic ointment; q 8 h); cephalexin (22 mg/kg [10 mg/lb], PO, q 12 h) with topically applied oxytetracycline ophthalmic ointment (q 8 h); or a control treatment of cephalexin (22 mg/kg, PO, q 12 h) with topically applied triple antibiotic ointment (q 8 h). Healing was monitored via measurements of the wound with calipers and evaluation of photographs obtained every 2 weeks. Treatment effectiveness was evaluated by wound healing and decreased signs of pain.
  
  
  RESULTS
  The Boxer breed was overrepresented in all groups. At the 2-week time point, wound healing was significantly more common in small-breed dogs, compared with large-breed dogs. Dogs treated with oxytetracycline ophthalmic ointment had a significantly shorter healing time than did dogs receiving the control treatment. Corneal ulcers in dogs that received doxycycline PO healed more rapidly than did ulcers in dogs in the control treatment group; however, this difference was not significant.
  
  
  CONCLUSIONS
  Topical tetracycline ophthalmic ointment was a safe, inexpensive, and effective adjunctive treatment for refractory corneal ulcers in dogs.
authors: College of Optometry, The Ohio State University, Columbus, OH 43210, USA. chandler.111@osu.edu
authors: Heather L
authors: HL
authors: Chandler
authors: Anne J
authors: AJ
authors: Gemensky-Metzler
authors: I Dineli
authors: ID
authors: Bras
authors: Terah E
authors: TE
authors: Robbin-Webb
authors: William J A
authors: WJ
authors: Saville
authors: Carmen M H
authors: CM
authors: Colitz
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002506:Cephalexin / Q000008:administration & dosage / Q000627:therapeutic use; D003320:Corneal Ulcer / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use*; D004333:Drug Administration Routes; D005260:Female; D008297:Male; D010118:Oxytetracycline / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D004318:Doxycycline; D002506:Cephalexin; D010118:Oxytetracycline